Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis
Objective: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI). Design: Retrospective observational study with data obtained from prospective registries. Set...
Gespeichert in:
| Veröffentlicht in: | British heart journal 2002-09, Vol.88 (3), p.260-265 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 265 |
|---|---|
| container_issue | 3 |
| container_start_page | 260 |
| container_title | British heart journal |
| container_volume | 88 |
| creator | Hsu, L F Mak, K H Lau, K W Sim, L L Chan, C Koh, T H Chuah, S C Kam, R Ding, Z P Teo, W S Lim, Y L |
| description | Objective: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI). Design: Retrospective observational study with data obtained from prospective registries. Setting: Tertiary cardiovascular institution with 24 hour acute interventional facilities. Patients: 202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset. Interventions: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%). Main outcome measures: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed. Results: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis. Conclusion: Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment. |
| doi_str_mv | 10.1136/heart.88.3.260 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1767339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A91138968</galeid><sourcerecordid>A91138968</sourcerecordid><originalsourceid>FETCH-LOGICAL-b618t-b3544b143dfcc171150093bd7da3bbab1f05f862af8724dfb782b774eb16ef743</originalsourceid><addsrcrecordid>eNqFkl-L1DAUxYso7rr66qMEFwXBGZOmbdIXYRnUVQZ98c--hSRNZjK2yZik6nwAv7d3nGF3lAEpoaH3d09vTk5RPCR4SghtXiyNjHnK-ZROywbfKk5J1fBJicnVbdjTup40mLKT4l5KK4xx1fLmbnFCSsK367T4Neudd1r2KIxZh8EkFCxay-yMzwn9cHmJOieVyVAZTN-7PCYkfYekHrNBwyZoGYHokfNWRp1d8ChHI7Ppdu3r6AYZN9C0cGHdy5Q3KERknYrOh36TXLpf3LGyT-bB_n1WfHr96uPscjL_8Obt7GI-UQ3heaJoXVWKVLSzWhNGSI1xS1XHOkmVkopYXFvelNJyVladVYyXirHKKNIYyyp6Vrzc6a5HNZhOwxmj7MV-QhGkE39XvFuKRfguCGsYpS0IPN0LxPBtNCmLwSUNtkhvwpgEIy2vGd6C5_-AqzBGD4cDLY5ZS2nFgHq8oxayNwIMDPBXvZUUFy3cL28bDtDzI9DCeAMTBm-sg8-H-OQIDk9nBqeP8dMdr2NIKRp7bQfBYpsx8SdjgnNBBWQMGh4dmniD70MFwJM9IBMky0bptUs3HOUVLfHBpC5l8_O6LuNXAW6zWrz_PBPlfH75hbXvxBXwz3a8Glb_G_I3m0P6fg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780793347</pqid></control><display><type>article</type><title>Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Hsu, L F ; Mak, K H ; Lau, K W ; Sim, L L ; Chan, C ; Koh, T H ; Chuah, S C ; Kam, R ; Ding, Z P ; Teo, W S ; Lim, Y L</creator><creatorcontrib>Hsu, L F ; Mak, K H ; Lau, K W ; Sim, L L ; Chan, C ; Koh, T H ; Chuah, S C ; Kam, R ; Ding, Z P ; Teo, W S ; Lim, Y L</creatorcontrib><description>Objective: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI). Design: Retrospective observational study with data obtained from prospective registries. Setting: Tertiary cardiovascular institution with 24 hour acute interventional facilities. Patients: 202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset. Interventions: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%). Main outcome measures: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed. Results: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis. Conclusion: Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.</description><identifier>ISSN: 1355-6037</identifier><identifier>ISSN: 0007-0769</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/heart.88.3.260</identifier><identifier>PMID: 12181218</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Cardiovascular Society</publisher><subject><![CDATA[Abciximab ; acute myocardial infarction ; Aged ; AMI ; Angioplasty ; Angioplasty, Balloon, Coronary - methods ; Antibodies, Monoclonal - administration & dosage ; Anticoagulants - administration & dosage ; Biological and medical sciences ; CADILLAC ; Cardiac patients ; Clinical outcomes ; controlled abciximab and device investigation to lower late angioplasty complications ; diabetes ; Diabetic Angiopathies - therapy ; Diabetics ; Diseases of the cardiovascular system ; Drug Therapy, Combination ; EPILOG ; EPISTENT ; evaluation of platelet IIb/IIIa inhibitor for stenting trial ; evaluation of PTCA to improve long-term outcome by c73E3 glycoprotein IIb/IIIa receptor blockade ; fibrinolysis ; Fibrinolytic Agents - administration & dosage ; global use of strategies to open occluded coronary arteries in acute coronary syndromes ; GUSTO-IIb ; Health aspects ; Heart attacks ; Hospitalization ; Humans ; Immunoglobulin Fab Fragments - administration & dosage ; Interventional Cardiology and Surgery ; Medical sciences ; Middle Aged ; Multivariate Analysis ; myocardial infarction ; Myocardial Infarction - therapy ; Patients ; percutaneous transluminal coronary angioplasty ; PTCA ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; recombinant tissue-type plasminogen activator ; Recurrence ; Retrospective Studies ; rt-PA ; Stents ; Streptokinase - administration & dosage ; Surgery ; target vessel revascularisation ; thrombolysis in myocardial infarction ; TIMI ; Tissue Plasminogen Activator - administration & dosage ; Transluminal angioplasty ; Treatment Outcome ; TVR ; Veins & arteries]]></subject><ispartof>British heart journal, 2002-09, Vol.88 (3), p.260-265</ispartof><rights>Copyright 2002 by Heart</rights><rights>2002 INIST-CNRS</rights><rights>COPYRIGHT 2002 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2002 Copyright 2002 by Heart</rights><rights>Copyright © Copyright 2002 by Heart 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b618t-b3544b143dfcc171150093bd7da3bbab1f05f862af8724dfb782b774eb16ef743</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767339/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767339/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13843208$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12181218$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hsu, L F</creatorcontrib><creatorcontrib>Mak, K H</creatorcontrib><creatorcontrib>Lau, K W</creatorcontrib><creatorcontrib>Sim, L L</creatorcontrib><creatorcontrib>Chan, C</creatorcontrib><creatorcontrib>Koh, T H</creatorcontrib><creatorcontrib>Chuah, S C</creatorcontrib><creatorcontrib>Kam, R</creatorcontrib><creatorcontrib>Ding, Z P</creatorcontrib><creatorcontrib>Teo, W S</creatorcontrib><creatorcontrib>Lim, Y L</creatorcontrib><title>Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis</title><title>British heart journal</title><addtitle>Heart</addtitle><description>Objective: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI). Design: Retrospective observational study with data obtained from prospective registries. Setting: Tertiary cardiovascular institution with 24 hour acute interventional facilities. Patients: 202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset. Interventions: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%). Main outcome measures: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed. Results: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis. Conclusion: Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.</description><subject>Abciximab</subject><subject>acute myocardial infarction</subject><subject>Aged</subject><subject>AMI</subject><subject>Angioplasty</subject><subject>Angioplasty, Balloon, Coronary - methods</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Anticoagulants - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>CADILLAC</subject><subject>Cardiac patients</subject><subject>Clinical outcomes</subject><subject>controlled abciximab and device investigation to lower late angioplasty complications</subject><subject>diabetes</subject><subject>Diabetic Angiopathies - therapy</subject><subject>Diabetics</subject><subject>Diseases of the cardiovascular system</subject><subject>Drug Therapy, Combination</subject><subject>EPILOG</subject><subject>EPISTENT</subject><subject>evaluation of platelet IIb/IIIa inhibitor for stenting trial</subject><subject>evaluation of PTCA to improve long-term outcome by c73E3 glycoprotein IIb/IIIa receptor blockade</subject><subject>fibrinolysis</subject><subject>Fibrinolytic Agents - administration & dosage</subject><subject>global use of strategies to open occluded coronary arteries in acute coronary syndromes</subject><subject>GUSTO-IIb</subject><subject>Health aspects</subject><subject>Heart attacks</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - administration & dosage</subject><subject>Interventional Cardiology and Surgery</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>myocardial infarction</subject><subject>Myocardial Infarction - therapy</subject><subject>Patients</subject><subject>percutaneous transluminal coronary angioplasty</subject><subject>PTCA</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>recombinant tissue-type plasminogen activator</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>rt-PA</subject><subject>Stents</subject><subject>Streptokinase - administration & dosage</subject><subject>Surgery</subject><subject>target vessel revascularisation</subject><subject>thrombolysis in myocardial infarction</subject><subject>TIMI</subject><subject>Tissue Plasminogen Activator - administration & dosage</subject><subject>Transluminal angioplasty</subject><subject>Treatment Outcome</subject><subject>TVR</subject><subject>Veins & arteries</subject><issn>1355-6037</issn><issn>0007-0769</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkl-L1DAUxYso7rr66qMEFwXBGZOmbdIXYRnUVQZ98c--hSRNZjK2yZik6nwAv7d3nGF3lAEpoaH3d09vTk5RPCR4SghtXiyNjHnK-ZROywbfKk5J1fBJicnVbdjTup40mLKT4l5KK4xx1fLmbnFCSsK367T4Neudd1r2KIxZh8EkFCxay-yMzwn9cHmJOieVyVAZTN-7PCYkfYekHrNBwyZoGYHokfNWRp1d8ChHI7Ppdu3r6AYZN9C0cGHdy5Q3KERknYrOh36TXLpf3LGyT-bB_n1WfHr96uPscjL_8Obt7GI-UQ3heaJoXVWKVLSzWhNGSI1xS1XHOkmVkopYXFvelNJyVladVYyXirHKKNIYyyp6Vrzc6a5HNZhOwxmj7MV-QhGkE39XvFuKRfguCGsYpS0IPN0LxPBtNCmLwSUNtkhvwpgEIy2vGd6C5_-AqzBGD4cDLY5ZS2nFgHq8oxayNwIMDPBXvZUUFy3cL28bDtDzI9DCeAMTBm-sg8-H-OQIDk9nBqeP8dMdr2NIKRp7bQfBYpsx8SdjgnNBBWQMGh4dmniD70MFwJM9IBMky0bptUs3HOUVLfHBpC5l8_O6LuNXAW6zWrz_PBPlfH75hbXvxBXwz3a8Glb_G_I3m0P6fg</recordid><startdate>20020901</startdate><enddate>20020901</enddate><creator>Hsu, L F</creator><creator>Mak, K H</creator><creator>Lau, K W</creator><creator>Sim, L L</creator><creator>Chan, C</creator><creator>Koh, T H</creator><creator>Chuah, S C</creator><creator>Kam, R</creator><creator>Ding, Z P</creator><creator>Teo, W S</creator><creator>Lim, Y L</creator><general>BMJ Publishing Group Ltd and British Cardiovascular Society</general><general>BMJ</general><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>Copyright 2002 by Heart</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20020901</creationdate><title>Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis</title><author>Hsu, L F ; Mak, K H ; Lau, K W ; Sim, L L ; Chan, C ; Koh, T H ; Chuah, S C ; Kam, R ; Ding, Z P ; Teo, W S ; Lim, Y L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b618t-b3544b143dfcc171150093bd7da3bbab1f05f862af8724dfb782b774eb16ef743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Abciximab</topic><topic>acute myocardial infarction</topic><topic>Aged</topic><topic>AMI</topic><topic>Angioplasty</topic><topic>Angioplasty, Balloon, Coronary - methods</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Anticoagulants - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>CADILLAC</topic><topic>Cardiac patients</topic><topic>Clinical outcomes</topic><topic>controlled abciximab and device investigation to lower late angioplasty complications</topic><topic>diabetes</topic><topic>Diabetic Angiopathies - therapy</topic><topic>Diabetics</topic><topic>Diseases of the cardiovascular system</topic><topic>Drug Therapy, Combination</topic><topic>EPILOG</topic><topic>EPISTENT</topic><topic>evaluation of platelet IIb/IIIa inhibitor for stenting trial</topic><topic>evaluation of PTCA to improve long-term outcome by c73E3 glycoprotein IIb/IIIa receptor blockade</topic><topic>fibrinolysis</topic><topic>Fibrinolytic Agents - administration & dosage</topic><topic>global use of strategies to open occluded coronary arteries in acute coronary syndromes</topic><topic>GUSTO-IIb</topic><topic>Health aspects</topic><topic>Heart attacks</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - administration & dosage</topic><topic>Interventional Cardiology and Surgery</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>myocardial infarction</topic><topic>Myocardial Infarction - therapy</topic><topic>Patients</topic><topic>percutaneous transluminal coronary angioplasty</topic><topic>PTCA</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>recombinant tissue-type plasminogen activator</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>rt-PA</topic><topic>Stents</topic><topic>Streptokinase - administration & dosage</topic><topic>Surgery</topic><topic>target vessel revascularisation</topic><topic>thrombolysis in myocardial infarction</topic><topic>TIMI</topic><topic>Tissue Plasminogen Activator - administration & dosage</topic><topic>Transluminal angioplasty</topic><topic>Treatment Outcome</topic><topic>TVR</topic><topic>Veins & arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hsu, L F</creatorcontrib><creatorcontrib>Mak, K H</creatorcontrib><creatorcontrib>Lau, K W</creatorcontrib><creatorcontrib>Sim, L L</creatorcontrib><creatorcontrib>Chan, C</creatorcontrib><creatorcontrib>Koh, T H</creatorcontrib><creatorcontrib>Chuah, S C</creatorcontrib><creatorcontrib>Kam, R</creatorcontrib><creatorcontrib>Ding, Z P</creatorcontrib><creatorcontrib>Teo, W S</creatorcontrib><creatorcontrib>Lim, Y L</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hsu, L F</au><au>Mak, K H</au><au>Lau, K W</au><au>Sim, L L</au><au>Chan, C</au><au>Koh, T H</au><au>Chuah, S C</au><au>Kam, R</au><au>Ding, Z P</au><au>Teo, W S</au><au>Lim, Y L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis</atitle><jtitle>British heart journal</jtitle><addtitle>Heart</addtitle><date>2002-09-01</date><risdate>2002</risdate><volume>88</volume><issue>3</issue><spage>260</spage><epage>265</epage><pages>260-265</pages><issn>1355-6037</issn><issn>0007-0769</issn><eissn>1468-201X</eissn><abstract>Objective: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI). Design: Retrospective observational study with data obtained from prospective registries. Setting: Tertiary cardiovascular institution with 24 hour acute interventional facilities. Patients: 202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset. Interventions: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%). Main outcome measures: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed. Results: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis. Conclusion: Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Cardiovascular Society</pub><pmid>12181218</pmid><doi>10.1136/heart.88.3.260</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-6037 |
| ispartof | British heart journal, 2002-09, Vol.88 (3), p.260-265 |
| issn | 1355-6037 0007-0769 1468-201X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1767339 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Abciximab acute myocardial infarction Aged AMI Angioplasty Angioplasty, Balloon, Coronary - methods Antibodies, Monoclonal - administration & dosage Anticoagulants - administration & dosage Biological and medical sciences CADILLAC Cardiac patients Clinical outcomes controlled abciximab and device investigation to lower late angioplasty complications diabetes Diabetic Angiopathies - therapy Diabetics Diseases of the cardiovascular system Drug Therapy, Combination EPILOG EPISTENT evaluation of platelet IIb/IIIa inhibitor for stenting trial evaluation of PTCA to improve long-term outcome by c73E3 glycoprotein IIb/IIIa receptor blockade fibrinolysis Fibrinolytic Agents - administration & dosage global use of strategies to open occluded coronary arteries in acute coronary syndromes GUSTO-IIb Health aspects Heart attacks Hospitalization Humans Immunoglobulin Fab Fragments - administration & dosage Interventional Cardiology and Surgery Medical sciences Middle Aged Multivariate Analysis myocardial infarction Myocardial Infarction - therapy Patients percutaneous transluminal coronary angioplasty PTCA Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) recombinant tissue-type plasminogen activator Recurrence Retrospective Studies rt-PA Stents Streptokinase - administration & dosage Surgery target vessel revascularisation thrombolysis in myocardial infarction TIMI Tissue Plasminogen Activator - administration & dosage Transluminal angioplasty Treatment Outcome TVR Veins & arteries |
| title | Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T02%3A42%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20of%20patients%20with%20diabetes%20mellitus%20and%20acute%20myocardial%20infarction%20treated%20with%20primary%20angioplasty%20or%20fibrinolysis&rft.jtitle=British%20heart%20journal&rft.au=Hsu,%20L%20F&rft.date=2002-09-01&rft.volume=88&rft.issue=3&rft.spage=260&rft.epage=265&rft.pages=260-265&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/heart.88.3.260&rft_dat=%3Cgale_pubme%3EA91138968%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780793347&rft_id=info:pmid/12181218&rft_galeid=A91138968&rfr_iscdi=true |